UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Seminars in oncology, ISSN 0093-7754, 12/2015, Volume 42, Issue 6, pp. S3 - S11
Life Sciences & Biomedicine | Oncology | Science & Technology | Immunotherapy - methods | Signal Transduction | Melanoma - immunology | Humans | Melanoma - drug therapy | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Combined Modality Therapy | CTLA-4 Antigen - antagonists & inhibitors | Immunotherapy - adverse effects | Index Medicus
Journal Article
The oncologist (Dayton, Ohio), ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Nature medicine, ISSN 1078-8956, 08/2018, Volume 24, Issue 8, pp. 1178 - 1191
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Lymphocytes - metabolism | Cell Survival | Dendritic Cells - immunology | Humans | Cell Communication | Melanoma - pathology | Tumor Microenvironment - immunology | Melanoma - immunology | Immunotherapy | Survival Analysis | Antigens, Surface - metabolism | Killer Cells, Natural - immunology | Membrane Proteins - metabolism | Care and treatment | Usage | Killer cells | Immune response | Dendritic cells | Research | Health aspects | Cancer | FLT3L protein | Cell survival | PD-1 protein | Melanoma | Cytotoxicity | Abundance | Lymphocytes T | T cell receptors | Gene expression | Ablation | Lymphocytes | Microenvironments | Natural killer cells | Human behavior | Tumors | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2018, Volume 19, Issue 7, pp. 852 - 853
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Public health. Hygiene-occupational medicine | Public health. Hygiene | General aspects | Miscellaneous | Dermatology | Biological and medical sciences | Medical sciences | Drug Eruptions - etiology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Adolescent | Adult | Female | Aged | Pruritus - chemically induced | Dose-response relationship (Biochemistry) | Pharmacology, Experimental | Research | Drug therapy | Melanoma | Antigens | Cytotoxicity | Metastasis | Kinases | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e21038 - e21038
Journal Article
The lancet oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 157 - 159
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - immunology | Kaplan-Meier Estimate | Treatment Outcome | Melanoma - pathology | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Aged | Melanoma - mortality | Chemotherapy | Hospitals | Melanoma | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2019, Volume 20, Issue 9, pp. 1239 - 1251
Journal Article
Human vaccines & immunotherapeutics, ISSN 2164-5515, 09/2018, Volume 14, Issue 9, pp. 2178 - 2182
melanoma | cancer | microbiome | oncology | immunotherapy | gut | Immunology | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Cancer Vaccines - immunology | Immunotherapy - methods | Animals | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - immunology | CTLA-4 Antigen - antagonists & inhibitors | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Melanoma - drug therapy | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Programmed Cell Death 1 Receptor - immunology | Melanoma - mortality | Prognosis | Melanoma | Dosage and administration | Research | Comparative analysis | Drug therapy | PD-1 protein | Toxicity | Body weight | Patients | Pembrolizumab | Chemotherapy | Immune checkpoint | Cell death | Immunotherapy | Antitumor activity | Mutation | Apoptosis | Immune system | Fees & charges | Laboratories | Equity | Equity stake | Response rates | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article